1 min read
Add as a preferred source on Google

Eloxx Pharmaceuticals Posts $0.49 Q3 GAAP Loss Per Share, Beats Estimate

Cash and cash equivalents were $56.3 million on Sept. 30, down from $62 million on June 30. The company said it believes its cash can fund operations into 2028.

A single cash cassette rests in an otherwise empty steel drawer / TokenPost.ai
A single cash cassette rests in an otherwise empty steel drawer / TokenPost.ai

Eloxx Pharmaceuticals’ cash and cash equivalents fell to $56.3 million by Sept. 30, while its third-quarter loss per share came in 9 cents better than estimated.

GAAP earnings per share was a loss of $0.49 for the quarter. Cash and cash equivalents totaled $62 million on June 30.

Eloxx said it believes its cash and cash equivalents will be sufficient to fund operations into 2028.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…